Last reviewed · How we verify

NCT04984200

Assessment of EyeArt Performance With Retinal Cameras

Completed Last updated 9 November 2022
What this trial tests

trial testing Retinal imaging in Diabetic Retinopathy in 246 participants. Completed in 19 August 2022.

Timeline
13 July 2021
Primary endpoint
19 August 2022
19 August 2022

Quick facts

Lead sponsorEyenuk, Inc.
StatusCompleted
Study typeOBSERVATIONAL
Enrollment246
Start date13 July 2021
Primary completion19 August 2022
Estimated completion19 August 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Eyenuk, Inc. — full company profile →

Who can join

22 and older, any sex, with Diabetic Retinopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study evaluates the performance of the EyeArt system for detecting diabetic retinopathy from images captured using retinal cameras and operators.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Retinal imaging

Trials testing the same drug.

Other recruiting trials for Diabetic Retinopathy

Currently open trials in the same condition.

Other Eyenuk, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04984200.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing